Suppr超能文献

PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

作者信息

Zhang Yiqun, Kwok-Shing Ng Patrick, Kucherlapati Melanie, Chen Fengju, Liu Yuexin, Tsang Yiu Huen, de Velasco Guillermo, Jeong Kang Jin, Akbani Rehan, Hadjipanayis Angela, Pantazi Angeliki, Bristow Christopher A, Lee Eunjung, Mahadeshwar Harshad S, Tang Jiabin, Zhang Jianhua, Yang Lixing, Seth Sahil, Lee Semin, Ren Xiaojia, Song Xingzhi, Sun Huandong, Seidman Jonathan, Luquette Lovelace J, Xi Ruibin, Chin Lynda, Protopopov Alexei, Westbrook Thomas F, Shelley Carl Simon, Choueiri Toni K, Ittmann Michael, Van Waes Carter, Weinstein John N, Liang Han, Henske Elizabeth P, Godwin Andrew K, Park Peter J, Kucherlapati Raju, Scott Kenneth L, Mills Gordon B, Kwiatkowski David J, Creighton Chad J

机构信息

Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.

Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

Abstract

Molecular alterations involving the PI3K/AKT/mTOR pathway (including mutation, copy number, protein, or RNA) were examined across 11,219 human cancers representing 32 major types. Within specific mutated genes, frequency, mutation hotspot residues, in silico predictions, and functional assays were all informative in distinguishing the subset of genetic variants more likely to have functional relevance. Multiple oncogenic pathways including PI3K/AKT/mTOR converged on similar sets of downstream transcriptional targets. In addition to mutation, structural variations and partial copy losses involving PTEN and STK11 showed evidence for having functional relevance. A substantial fraction of cancers showed high mTOR pathway activity without an associated canonical genetic or genomic alteration, including cancers harboring IDH1 or VHL mutations, suggesting multiple mechanisms for pathway activation.

摘要

在代表32种主要类型的11219例人类癌症中,检测了涉及PI3K/AKT/mTOR途径的分子改变(包括突变、拷贝数、蛋白质或RNA)。在特定的突变基因中,频率、突变热点残基、计算机模拟预测和功能测定在区分更可能具有功能相关性的遗传变异子集方面都具有参考价值。包括PI3K/AKT/mTOR在内的多个致癌途径汇聚于相似的下游转录靶点集。除了突变,涉及PTEN和STK11的结构变异和部分拷贝缺失也显示出具有功能相关性的证据。相当一部分癌症显示出高mTOR途径活性,但没有相关的典型遗传或基因组改变,包括携带IDH1或VHL突变的癌症,这表明途径激活存在多种机制。

相似文献

1
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
2
Pan-Cancer Analysis Pinpoints Targets in PI3K Pathway.泛癌分析锁定 PI3K 通路中的靶点。
Cancer Discov. 2017 Aug;7(8):OF6. doi: 10.1158/2159-8290.CD-NB2017-092. Epub 2017 Jun 15.
3
Oncogenic Roles of the PI3K/AKT/mTOR Axis.PI3K/AKT/mTOR 轴的致癌作用。
Curr Top Microbiol Immunol. 2017;407:153-189. doi: 10.1007/82_2017_6.
6
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.乳腺癌肝转移中PI3K-AKT-mTOR信号通路激活的富集
Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.
8
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.PI3K/AKT/mTOR 通路作为子宫内膜癌的治疗靶点。
Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Epub 2012 Oct 18.
9
[Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].[造血干细胞中PI3K/AKT/mTOR信号通路的最新研究]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):245-9. doi: 10.7534/j.issn.1009-2137.2013.01.050.

引用本文的文献

本文引用的文献

2
Emerging role of mTOR in the response to cancer therapeutics.mTOR在癌症治疗反应中的新作用。
Trends Cancer. 2016 May;2(5):241-251. doi: 10.1016/j.trecan.2016.03.008.
8
The PI3K/AKT Pathway as a Target for Cancer Treatment.PI3K/AKT 通路作为癌症治疗的靶点。
Annu Rev Med. 2016;67:11-28. doi: 10.1146/annurev-med-062913-051343. Epub 2015 Oct 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验